Rilonacept and canakinumab

British Journal of Clinical Pharmacology

Volumn 71, Issue 5, 2011, Pages 639-641

  Dubois, Eline A ^a   Rissmann, Robert ^a   Cohen, Adam F ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CANAKINUMAB; CRYOPYRIN; CYTOKINE; INTERLEUKIN 1BETA; NEW DRUG; ORPHAN DRUG; REGENERON; RILONACEPT; UNCLASSIFIED DRUG;

ARTICLE; CINCA SYNDROME; COLD URTICARIA; CYTOKINE PRODUCTION; DRUG DOSE REDUCTION; DRUG INDICATION; DRUG MECHANISM; FAMILIAL DISEASE; GENE MUTATION; HEADACHE; HUMAN; IMMUNE RESPONSE; INFLAMMATORY DISEASE; INJECTION SITE REACTION; JUVENILE RHEUMATOID ARTHRITIS; MUCKLE WELLS SYNDROME; NEWBORN; NEWBORN DISEASE; ONSET AGE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; RHEUMATOID ARTHRITIS; SINUSITIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES; HUMANS; INTERLEUKIN-1BETA; RECOMBINANT FUSION PROTEINS;

EID: 79953886264     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2011.03958.x     Document Type: Article

References (6)

1. Available at
2. Hofman HM, Yasothan U, Kirkpatrick P. Fresh from the pipeline: rilonacept. Nat Rev Drug Discov 2008; 7: 385-6.
3. Available at
4. Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, Leslie KS, Hachulla E, Quartier P, Gitton X, Widmer A, Patel N, Hawkins PH, for the Canakinumab in CAPS Study Group. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 2009; 360: 2416-25.
5. Stahl N, Radin A, Mellis S. Rilonacept - CAPS and beyond. Ann N Y Acad Sci 2009; 1182: 124-34.
6. Geyer M, Müller-Ladner U. Actual status of anti-interleukin-1 therapies in rheumatic diseases. Curr Opin Rheumatol 2010; 22: 246-51.